CLINICAL TRIALS PROFILE FOR SEMAPIMOD
✉ Email this page to a colleague
Clinical Trials for Semapimod
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00038766 ↗ | CNI-1493 for Treatment of Moderate to Severe Crohn's Disease | Terminated | Ferring Pharmaceuticals | Phase 2 | The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease. |
NCT00739986 ↗ | Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo | Completed | Ferring Pharmaceuticals | Phase 2 | Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD). |
NCT00740103 ↗ | Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease | Completed | Ferring Pharmaceuticals | Phase 2 | CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Activity Index (CDAI). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Semapimod
Condition Name
Clinical Trial Locations for Semapimod
Trials by Country
Clinical Trial Progress for Semapimod
Clinical Trial Phase
Clinical Trial Sponsors for Semapimod
Sponsor Name